LENZ Therapeutics Reports $1.9 Million Revenue in Q1 2026, Net Loss of $41.5 Million

LENZ Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $1.9 million, a significant increase from zero revenue in the same period last year. This revenue was primarily driven by product sales of $1.7 million from its recently launched VIZZ® (aceclidine ophthalmic solution) 1.44%, which received FDA approval in July 2025. The company also recognized $250,000 in license revenue, attributed to an upfront payment under a new licensing agreement. Despite this revenue generation, LENZ reported a net loss of $41.5 million for the quarter, compared to a net loss of $14.6 million in the prior year, reflecting increased operational costs associated with its commercialization efforts.

Operating expenses surged to $46.0 million in the first quarter of 2026, up from $16.9 million in the same quarter of 2025. This increase was largely due to a 305% rise in selling, general, and administrative expenses, which reached $45.0 million. The company attributed this spike to the costs associated with launching a direct-to-consumer marketing campaign and expanding its sales force. Research and development expenses, however, dropped to zero from $5.8 million, as costs related to VIZZ's production were reclassified to selling and administrative expenses following its FDA approval.

In terms of operational metrics, LENZ reported approximately 25,000 paid and filled monthly prescriptions for VIZZ during the quarter. The company has also expanded its sales force from 88 to 117 territories, indicating a strategic push to enhance market penetration. As of March 31, 2026, LENZ had cash, cash equivalents, and marketable securities totaling $258.4 million, which the company believes will support its operations for at least the next 12 months. The accumulated deficit stood at $268.6 million, reflecting the ongoing costs associated with product development and commercialization.

Strategically, LENZ has been active in establishing licensing agreements to expand its market reach. The company entered into several agreements, including a distribution agreement for VIZZ in the Middle East and licensing agreements in Southeast Asia and Canada, which could provide additional revenue streams in the future. The company is also pursuing regulatory approvals in international markets, having submitted marketing authorization applications to both the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency.

Looking ahead, LENZ anticipates continued investment in its commercialization efforts for VIZZ, which it views as a significant opportunity in a market estimated to exceed $3 billion in the U.S. The company expects to incur additional losses as it builds its infrastructure and marketing capabilities. While it believes its current financial resources will be sufficient to reach positive operating cash flow, LENZ acknowledges the potential need for additional financing to support its growth initiatives.